Cow Dung Extract Inhibited Testosterone-Induced Benign Prostatic Hyperplasia (BPH) In Wistar Rats
Barre latérale de l'article
Contenu principal de l'article
Résumé
Animal dungs could be a veritable source of steroidal and/or non-steroidal 5? -reductase inhibitory anti-Benign Prostatic Hyperplasia (BPH) drugs. A methanol cow dung extract was therefore evaluated for its possible anti-BPH act ivity in vivo in rats. Male Wistar albino rats (48) were randomly sorted into six groups of 8. Prostate hyperplasia was induced in five of the groups by a 30- day daily subcutaneous administration of 3mg/kg testosterone. One (the control) of these BPH model groups received a testosterone only regimen while each of the remaining four received orally the BPH-inducing testosterone concurrently with one of 100mg/kg, 200mg/kg, 400mg/kg cow dung extract or 10mg/kg finasteride (standard reference). The sixth group (bland) received olive oil and 2% tween 20, the respective vehicles for the hyperplasia-inducing subcutaneous
testosterone and the remedial oral extract/finasteride. Each animal was sacrificed on the 31st day, its prostate removed, weighed and prostate weight/100g animal subsequently determined.Testosterone was found to produce a highly significant increase (p < 0.0001) in prostate weight after a 30-day daily administration. Likewise, cow dung extract was found to cause a highly significant inhibition (p < 0.0001) of the testosteroneinduced prostate weight increase at 100mg/kg, 200mg/kg and 400mg/kg doses each. Cow dung could therefore be explored as a promising source of new 5?-reductase-inhibiting anti-BPH compounds.
Téléchargements
Renseignements sur l'article
Cette œuvre est sous licence Creative Commons Attribution - Pas d'Utilisation Commerciale - Pas de Modification 4.0 International.
Références
Aboelsoud NH (2010). Herbal medicine in ancient Egypt. Journal of Medicinal Plants Research. 4(2):082-086 Amis Jr ES (1994). Anatomy and Physiology of the Prostate In: Radiology of the Lower Urinary Tract Springer Berlin Heidelberg pp. 167-169
Basak AB, Lee MW and Lee TS (2002). In vitro inhibitory activity of cow urine and dung to Fusarium solani f. sp. cucurbitae. Mycobiology 30(1):51-54
Bhat SV, Nagasampagi BA and Sivakumar M (2005). Chemistry of natural products. Narosa Publishing House, New Delhi pp. 15-235, 585-660
Bosch JR, Hop WC, Kirkels WJ and Schröder FH (1995 ). Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community. Urology 46(3):34-40
Chapple CR, Wein AJ, Abrams P, Dmochowski RR, Giuliano F, Kaplan SA, McVary KT and Roehrborn CG (2008). Lower urinary tract symptoms revisited: a broader clinical perspective. European urology 54(3):563-569
Ezeanyika LU, Ejike CE, Obidoa O and Elom SO (2006). Prostate disorders in an apparently normal Nigerian population 1: Prevalence. Biokemistri18(2):127-132
Fitzpatrick JM and Artibani W (2006). Therapeutic strategies for managing BPH progression. European urology supplements 5(20):997-1003 Fullerton DS (1998). Steroids and Therapeutically related compounds. In: Delgado JN and Remers WA (eds). Textbook of organic medicinal and pharmaceutical chemistry. 10th edition, Lippincott-Raven Publishers, Philadelphia, USA, pp. 727-731
Gossel-Williams M, Davis A and O’Connor N (2006). Inhibition of testosterone- induced hyperplasia of the prostate of Sprague-Dawley rats by pumpkin seed oil. Journal of medicinal Foods 9(2):284-286
Hieble JP (2004). Therapeutic strategies for benign prostatic hypertrophy. Drug Discovery Today: Therapeutic Strategies 1(2):243-248.
Ilett KF, Tee LB, Reeves PT, Minchin RF (1990). Mebolism of drugs and other xenobiotics in the gut lumen and wall. Pharmacology & therapeutics 46(1):67-93 Isaacs JT(1993). Etiology of benign prostatic hyperplasia. European urology 25:6-9
Irwig MS(2012a ). Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects. The Journal of clinical psychiatry 73(9):1220-1223
Irwig MS (2012b ). Persistent sexual side effects of finasteride: could they be permanent? The journal of sexual medicine 9(11):2927-2932
Irwig MS and Kolukula S (2011). Persistent sexual side effects of finasteride for male pattern hair loss. The journal of sexual medicine 8(6):1747-1753
Keller TH, Pichota A and Yin ZA (2006). practical view of ‘druggability’. Current opinion in chemical biology 10 (4):357-61
Koehn FE and Carter GT (2005). The evolving role of natural products in drug discovery. Nature reviews Drug discovery 4(3):206-20
Kramer G, Mitteregger D and Marberger M (2007). Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? European urology 51(5):1202-1216
Mahato SB, Garai S (1997). Advances in microbial steroid biotransformation. Steroids 62(4):332-45
Mandavgane SA, Pattalwar VV and Kalambe AR ( 2005). Development of cow dung based herbal mosquito repellent. Natural product radiance 4(4):270-272
McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, Foster HE, Gonzalez CM, Kaplan SA, Penson DF and Ulchaker JC (2011). Update on AUA guideline on the management of benign prostatic hyperplasia. The Journal of urology 185(5):1793-803
Mull DS, Anderson JW and Mull JD (1990). Cow dung, rock salt, and medical innovation in the Hindu Kush of Pakistan: the cultural transformation of neonatal tetanus and iodine deficiency. Social Science & Medicine 30(6):675-91
Newman DJ and Cragg GM (2012). Natural products as sources of new drugs over the 30 years from 1981 to 2010. Journal of natural products 75(3):311-35
Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W and Pettersson S (2012). Host-gut microbiota metabolic interactions. Science 336(6086):1262-1267
Patel ND and Parsons JK (2014). Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. Indian journal of urology 30(2):170-176
Pelletier G, Luu-the VA, Huang XF, Lapointe H and Labrie F (1998). Localization by in situ hybridization of steroid 5 alpha-reductase isozyme gene expression in the human prostate and preputial skin. The Journal of urology 160(2):577-82.
Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Morrill B, Montorsi F and Comb AT (2008). The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. The Journal of urology 179(2):616-21
Rosenthal MD and Glew RH (2009). Medical Biochemistry, Human metabolism in health and disease. John Wiley, Hoboken, NJ. USA, pp.48-49
Sayin SI, Wahlström A, Felin J, Jäntti S, Marschall HU, Bamberg K, Angelin B, Hyötyläinen T, Oreši? M, Bäckhed F (2013). Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell metabolism 17(2):225-35
Silverman RB (2004). The organic chemistry of drug design and drug action. 2nd edition. Elsevier Academic Press. London, UK, p. 242
Trease GE and Evans WC (2002). Pharmacognosy. 15th Ed. London, Saunders Publishers, pp. 42–44, 221-229
Yang DM, Su SW, Li x, Zhu TR (1987). Studies on bioactive constituents from the excreta of Trogopterus xanthipes Milne . Acta Pharmaceutica Sinica 22(10):756-60